Early studies have shown that activation of NLRP3 induces adaptive immunity to tumors, and that IL-1β released during this process is required for the priming of IFN-γ-producing, tumor-antigen-specific CD8+ T cells [113]. This evidence concerns the gene IL1B and neoplasm.